Centromeres in cancer: Unraveling the link between chromosomal instability and tumorigenesis
Medical Oncology · 2024
DOI: 10.1007/s12032-024-02524-0 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medical Oncology, 2024. Verfasst von Mohsen Karami Fath und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cellular and Molecular Biology, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran. Hauptthemen laut MEDLINE: Chromosomal Instability, Neoplasms, Centromere, Carcinogenesis. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 284 Literaturangaben.
Abstract (Originalsprache)
Centromeres are critical structures involved in chromosome segregation, maintaining genomic stability, and facilitating the accurate transmission of genetic information. They are key in coordinating the assembly and help keep the correct structure, location, and function of the kinetochore, a proteinaceous structure vital for ensuring proper chromosome segregation during cell division. Abnormalities in centromere structure can lead to aneuploidy or chromosomal instability, which have been implicated in various diseases, including cancer. Accordingly, abnormalities in centromeres, such as structural rearrangements and dysregulation of centromere-associated proteins, disrupt gene function, leading to uncontrolled cell growth and tumor progression. For instance, altered expression of CENP-A, CENP-E, and others such as BUB1, BUBR1, MAD1, and INCENP, have been shown to ascribe to centromere over-amplification, chromosome missegregation, aneuploidy, and chromosomal instability; this, in turn, can culminate in tumor progression. These centromere abnormalities also promoted tumor heterogeneity by generating genetically diverse cell populations within tumors. Advanced techniques like fluorescence in situ hybridization (FISH) and chromosomal microarray analysis are crucial for detecting centromere abnormalities, enabling accurate cancer classification and tailored treatment strategies. Researchers are exploring strategies to disrupt centromere-associated proteins for targeted cancer therapies. Thus, this review explores centromere abnormalities in cancer, their molecular mechanisms, diagnostic implications, and therapeutic targeting. It aims to advance our understanding of centromeres' role in cancer and develop advanced diagnostic tools and targeted therapies for improved cancer management and treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cellular and Molecular Biology, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran.
- School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
- Department of Brain and Cognitive Sciences, Cell Science Research Center, ROYAN Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
- Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran.
- School of Medicine, Semnan University of Medical Sciences, Semnan, Iran.
- Department of Biochemistry, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.
Zitieren
APA
Karami Fath, M., Nazari, A., Parsania, N., Behboodi, P., Ketabi, S. S., Razmjouei, P., Farzam, F., Shafagh, S. G., & Nabi Afjadi, M. (2024). Centromeres in cancer: Unraveling the link between chromosomal instability and tumorigenesis. Medical Oncology. https://doi.org/10.1007/s12032-024-02524-0
Vancouver
Karami Fath M, Nazari A, Parsania N, Behboodi P, Ketabi SS, Razmjouei P, et al. Centromeres in cancer: Unraveling the link between chromosomal instability and tumorigenesis. Medical Oncology. 2024. doi:10.1007/s12032-024-02524-0
BibTeX
@article{KaramiFath2024,
author = {Karami Fath, Mohsen and Nazari, Ahmad and Parsania, Noushin and Behboodi, Paria and Ketabi, Seyedeh Sara and Razmjouei, Pegah and Farzam, Farnoosh and Shafagh, Seyyed-Ghavam and Nabi Afjadi, Mohsen},
title = {Centromeres in cancer: Unraveling the link between chromosomal instability and tumorigenesis},
journal = {Medical Oncology},
year = {2024},
doi = {10.1007/s12032-024-02524-0}
}
EUVIMED